Novartis

News

Novartis considers "pay-for-performance" for CAR-T

Novartis is considering a “pay-for-performance” pricing scheme if its CAR-T therapy gets approved, following trial results published earlier this week.

News

Teva plans migraine drug filing later this year

Blockbuster hopeful could launch next year if approved.

News

Novartis and IBM Watson form breast cancer pact

Partnership aims at improving outcomes in advanced breast cancer.

News

FDA to review Novartis CAR-T next month

If all goes well, FDA could approve CTL109 by late September

News

Sandoz files Humira and Remicade biosimilars in EU

European regulators to review Sandoz’s Humira and Remicade biosimilars.

News

Teva on track to file migraine blockbuster

Phase 3 success for fremanezumab.

Novartis considers "pay-for-performance" for CAR-T

Teva plans migraine drug filing later this year

Novartis and IBM Watson form breast cancer pact

FDA to review Novartis CAR-T next month

Sandoz files Humira and Remicade biosimilars in EU

Teva on track to file migraine blockbuster

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

Novartis

Editor's Picks